The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil

被引:22
|
作者
Schayek, Hagit [1 ]
De Marco, Luiz [2 ]
Starinsky-Elbaz, Sigal [1 ]
Rossette, Mariana [2 ]
Laitman, Yael [1 ]
Bastos-Rodrigues, Luciana [3 ]
da Silva Filho, Agnaldo Lopes [4 ]
Friedman, Eitan [1 ,5 ]
机构
[1] Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, IL-52621 Tel Hashomer, Israel
[2] Univ Fed Minas Gerais, Dept Surg, BR-30130100 Belo Horizonte, MG, Brazil
[3] Univ Fed Juiz Fora, Dept Basic Sci, BR-35010177 Governador Valadares, MG, Brazil
[4] Univ Fed Minas Gerais, Dept Gynecol & Obstet, BR-30130100 Belo Horizonte, MG, Brazil
[5] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
Population screening; recurring BRCA mutations; TP53 founder mutation; consecutive ovarian cancer cases; high risk families; HEREDITARY BREAST-CANCER; RISK-ASSESSMENT;
D O I
10.1016/j.cancergen.2015.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In Brazil, several recurring mutations in BRCA1 and BRCA2 and a TP53 mutation (R337H) have been reported in high risk breast cancer cases. We hypothesized that these recurring mutations may also be detected in the general population and ovarian cancer cases in the state of Minas Gerais. To test this notion, participants were recruited from the outpatient and the Gynecological clinic in the UFMG Medical Center in Belo Horizonte, Minas Gerais, Brazil. BRCA1 (c.68_69delAG, c.5266dupC, c.181T>G, c.4034delA, c.5123C>A), BRCA2 (c.5946deIT, c.8537_8538delAG, 4936_4939delGAAA), the c.156_157insAlu* BRCA2 and the c.1010G>A *TP53 mutation were genotyped using validated techniques. Overall, 513 cancer free participants (273 men) (mean age 47.7 +/- 15.1 years) and 103 ovarian cancer cases (mean age at diagnosis 58.7 +/- 9.6 years) were studied. None of the participants were found to carry any of the genotyped mutations. We conclude that the recurring mutations in BRCA1, BRCA2 and TP53 cannot be detected in the general population or consecutive ovarian cancer cases in this geographical region in Brazil.
引用
收藏
页码:50 / 52
页数:3
相关论文
共 50 条
  • [1] The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil
    Schayek, Hagit
    De Marco, Luiz
    Starinsky-Elbaz, Sigal
    Rossette, Mariana
    Laitman, Yael
    Bastos-Rodrigues, Luciana
    da Silva Filho, Agnaldo Lopes
    Friedman, Eitan
    CANCER GENETICS, 2016, 209 (06) : 283 - 284
  • [2] Commentary regarding Schayek et al., entitled "The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil"
    Luiz Vianna, Fernanda Sales
    Alemar, Barbara
    Achatz, Maria Isabel
    Camey, Suzi Alves
    Ashton-Prolla, Patricia
    CANCER GENETICS, 2016, 209 (06) : 282 - 283
  • [3] Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours
    Ramus, SJ
    Bobrow, LG
    Pharoah, PDP
    Finnigan, DS
    Fishman, A
    Altaras, M
    Harrington, PA
    Gayther, SA
    Ponder, BAJ
    Friedman, LS
    GENES CHROMOSOMES & CANCER, 1999, 25 (02): : 91 - 96
  • [4] Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations
    Ghezelayagh, Talayeh S.
    Pennington, Kathryn P.
    Norquist, Barbara M.
    Khasnavis, Nithisha
    Radke, Marc R.
    Kilgore, Mark R.
    Garcia, Rochelle L.
    Lee, Ming
    Katz, Ronit
    Leslie, Kimberly K.
    Risques, Rosa Ana
    Swisher, Elizabeth M.
    GYNECOLOGIC ONCOLOGY, 2021, 160 (03) : 786 - 792
  • [5] Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations
    Ganguly, Shuvadeep
    Gogia, Ajay
    LANCET ONCOLOGY, 2022, 23 (07): : E314 - E314
  • [6] High proportion of germline BRCA1 and BRCA2 mutations in unselected ovarian cancer
    Abrahamson, JLA
    Vesprini, DJ
    Mclaughlin, J
    Cole, D
    Rosen, B
    Bradley, L
    Robb, K
    Jack, E
    Rehal, P
    Morris, A
    Patterson, C
    Fan, I
    Brunel, JS
    Narod, SA
    Risch, HA
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A59 - A59
  • [7] BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Buerkle, Bernd
    Tempfer, Clemens
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 359 - 359
  • [8] Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations Reply
    Kristeleit, Rebecca
    Oza, Amit M.
    LANCET ONCOLOGY, 2022, 23 (07): : E315 - E315
  • [9] Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history
    Tonin, PN
    Mes-Masson, AM
    Narod, SA
    Ghadirian, P
    Provencher, D
    CLINICAL GENETICS, 1999, 55 (05) : 318 - 324
  • [10] Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN
    Blanco, A.
    Grana, B.
    Fachal, L.
    Santamarina, M.
    Cameselle-Teijeiro, J.
    Ruiz-Ponte, C.
    Carracedo, A.
    Vega, A.
    CLINICAL GENETICS, 2010, 77 (02) : 193 - 196